Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296096 | 1.00 | MEN1 (0.32) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL3179619 | 1.00 | MEN1 (0.32) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL14640259 | 0.88 | MEN1 (0.34) | MEN1KMT2AMAPK1CA12CA14 | |
| SCHEMBL2671553 | 0.88 | MEN1 (0.34) | MEN1KMT2AMAPK1CA12CA14 | |
| SCHEMBL23833792 | 0.88 | MEN1 (0.31) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL30198872 | 0.88 | MEN1 (0.31) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL30198800 | 0.88 | MEN1 (0.31) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL30198986 | 0.88 | MEN1 (0.31) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL30198838 | 0.88 | MEN1 (0.31) | MEN1KMT2AALDH1A1TSHRMAPK1 | |
| SCHEMBL19921767 | 0.87 | MEN1 (0.34) | MEN1KMT2AALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655321-B1 | PURIFICATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | GE HEALTHCARE LTD (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-9381259-B2 | Precursor compound of radioactive halogen-labeled organic compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20160082135-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
| US-9238596-B2 | Process simplification for precursor compound | GE HEALTHCARE LIMITED (GB) | 2016-01-19 | — | — | US | disclosed |
| US-9238596-B2 | Process simplification for precursor compound | GE HEALTHCARE LIMITED (GB) | 2016-01-19 | — | — | US | disclosed |
| US-9061977-B2 | Purification of precursor compound by crystallisation | GE HEALTHCARE LIMITED (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140213817-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | NIHON-MEDI-PHYSICS CO., LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8758724-B2 | Unnatural amino acid radiolabeling precursor | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20130274507-A1 | PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130274507-A1 | PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130267730-A1 | PURIFICIATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | GE HEALTHCARE LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130217908-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217908-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE LIMITED (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20120229804-A1 | BOROSILICATE GLASSWARE AND SILICA BASED QMA'S IN 18F NUCLEOPHILIC SUBSTITUTION: INFLUENCE OF ALUMINUM, BORON AND SILICON ON THE REACTIVITY OF THE 18F- ION | MEDI-PHYSICS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012084831-A1 | PURIFICATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | GE HEALTHCARE LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012055992-A2 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | GE HEALTHCARE LIMITED (GB) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213817-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | BCAT2, SLCO2B1, ORC3 | MEN1 3670/4885KMT2A 3576/4885ALDH1A1 2188/4885 |
| US-20130274507-A1 | PROCESS SIMPLIFICATION FOR PRECURSOR COMPOUND | PAICS, FGB, FIP1L1 | MEN1 228/4885KMT2A 3638/4885ALDH1A1 1462/4885 |
| US-20130267730-A1 | PURIFICIATION OF PRECURSOR COMPOUND BY CRYSTALLISATION | RFC1, PAICS, RFC2 | MEN1 541/4885KMT2A 4579/4885ALDH1A1 2720/4885 |
| US-20160082135-A1 | PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND | BCAT2, SLCO2B1, ORC3 | MEN1 3670/4885KMT2A 3576/4885ALDH1A1 2188/4885 |
| US-20130217908-A1 | STABILISATION OF RADIOPHARMACEUTICAL PRECURSORS | AADAT, QPCT, SLC1A5 | MEN1 26/4885KMT2A 2177/4885ALDH1A1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.